TWI813673B - 抗增生化合物及其用途 - Google Patents

抗增生化合物及其用途 Download PDF

Info

Publication number
TWI813673B
TWI813673B TW108114146A TW108114146A TWI813673B TW I813673 B TWI813673 B TW I813673B TW 108114146 A TW108114146 A TW 108114146A TW 108114146 A TW108114146 A TW 108114146A TW I813673 B TWI813673 B TW I813673B
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
nitrogen
ring
Prior art date
Application number
TW108114146A
Other languages
English (en)
Chinese (zh)
Other versions
TW202012400A (zh
Inventor
享利 余
麥可 克拉克
蓋 貝米斯
麥克 波伊德
基山 強圖帕拉
菲利浦 柯立爾
鄧紅波
董慧君
華倫 道許
羅素 R 胡佛
麥克 阿瑟 二世 強森
夏山科 庫卡尼
瑪琳那 佩妮
史帝文 羅金
達林 竹本
唐青
納桑 D 沃爾
天生 王
大衛 J 洛佛
李磐
Original Assignee
德商馬克專利公司
美商維泰克斯製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德商馬克專利公司, 美商維泰克斯製藥公司 filed Critical 德商馬克專利公司
Publication of TW202012400A publication Critical patent/TW202012400A/zh
Application granted granted Critical
Publication of TWI813673B publication Critical patent/TWI813673B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW108114146A 2018-04-24 2019-04-23 抗增生化合物及其用途 TWI813673B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862661719P 2018-04-24 2018-04-24
US62/661,719 2018-04-24

Publications (2)

Publication Number Publication Date
TW202012400A TW202012400A (zh) 2020-04-01
TWI813673B true TWI813673B (zh) 2023-09-01

Family

ID=66655429

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108114146A TWI813673B (zh) 2018-04-24 2019-04-23 抗增生化合物及其用途

Country Status (26)

Country Link
US (4) US10815225B2 (cg-RX-API-DMAC7.html)
EP (2) EP3784666B1 (cg-RX-API-DMAC7.html)
JP (2) JP7304892B2 (cg-RX-API-DMAC7.html)
KR (1) KR102813581B1 (cg-RX-API-DMAC7.html)
CN (1) CN112236428B (cg-RX-API-DMAC7.html)
AR (1) AR114496A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019261308B2 (cg-RX-API-DMAC7.html)
CA (1) CA3098335A1 (cg-RX-API-DMAC7.html)
CY (1) CY1125433T1 (cg-RX-API-DMAC7.html)
DK (2) DK3784666T3 (cg-RX-API-DMAC7.html)
ES (2) ES2987356T3 (cg-RX-API-DMAC7.html)
FI (1) FI4043460T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20241163T1 (cg-RX-API-DMAC7.html)
HU (2) HUE058746T2 (cg-RX-API-DMAC7.html)
IL (2) IL301501B2 (cg-RX-API-DMAC7.html)
LT (1) LT3784666T (cg-RX-API-DMAC7.html)
MX (1) MX2020011089A (cg-RX-API-DMAC7.html)
PL (2) PL3784666T3 (cg-RX-API-DMAC7.html)
PT (2) PT4043460T (cg-RX-API-DMAC7.html)
RS (1) RS63281B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202009500QA (cg-RX-API-DMAC7.html)
SI (1) SI3784666T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200308T1 (cg-RX-API-DMAC7.html)
TW (1) TWI813673B (cg-RX-API-DMAC7.html)
WO (1) WO2019209759A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006071B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301501B2 (en) 2018-04-24 2024-10-01 Vertex Pharma Antiproliferation compounds and uses thereof
WO2020010451A1 (en) * 2018-07-10 2020-01-16 Trillium Therapeutics Inc. Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists
WO2020236834A1 (en) * 2019-05-20 2020-11-26 Seshadri Raju Modified z stents for iliac vein stenting
CN115103840B (zh) 2019-12-20 2025-07-22 拜耳公司 取代的噻吩甲酰胺、噻吩甲酸及其衍生物
US20240132464A1 (en) * 2022-09-28 2024-04-25 Accutar Biotechnology Inc. Heterocyclic compounds as e3 ligase inhibitors
WO2025223536A1 (zh) * 2024-04-26 2025-10-30 正大天晴药业集团股份有限公司 稠合双环化合物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
WO2010114179A1 (en) * 2009-04-02 2010-10-07 Mitsubishi Tanabe Pharma Corporation 3-[1,4]oxazepane-4-pyrimidone derivatives
US20110136787A1 (en) * 2009-12-04 2011-06-09 Ryan Craig Schoenfeld Diphenyl azepane, diazepane and oxazepane derivatives and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
DE19840028A1 (de) 1998-09-02 2000-03-09 Max Planck Gesellschaft Nucleinsäuremoleküle codierend Enzyme, die Fructosyltransferaseaktivität besitzen, und deren Verwendung
OA12118A (en) 1999-12-10 2006-05-04 Pfizer Prod Inc PyrroloÄ2,3-dÜpyrimidine compounds.
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
KR100833371B1 (ko) 2001-04-27 2008-05-28 젠야쿠코교가부시키가이샤 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA05001766A (es) 2002-08-14 2005-08-19 Atugen Ag Uso de proteina quinasa n beta.
WO2004089925A1 (en) 2003-04-03 2004-10-21 Semafore Pharmaceuticals, Inc. Pi-3 kinase inhibitor prodrugs
ES2382377T3 (es) 2003-05-30 2012-06-07 Gemin X Pharmaceuticals Canada Inc. Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
WO2005007623A2 (en) 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
HRP20140975T1 (hr) 2005-10-07 2014-11-21 Exelixis, Inc. Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
KR101533461B1 (ko) 2006-04-26 2015-07-02 에프. 호프만-라 로슈 아게 Pi3k저해제로 유용한 티에노[3,2-d]피리미딘 유도체
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
HUE029188T2 (en) 2007-03-12 2017-03-28 Ym Biosciences Australia Pty Phenylamino-pyrimidine compounds and their use
US8394794B2 (en) 2007-03-23 2013-03-12 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
MY165582A (en) 2008-03-11 2018-04-05 Incyte Holdings Corp Azetidine and cyclobutane derivatives as jak inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8163763B2 (en) 2008-07-31 2012-04-24 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP3256132A1 (en) 2015-02-13 2017-12-20 Merck Patent GmbH Pyrimidine derivatives for use in the treatment of cancer
IL301501B2 (en) 2018-04-24 2024-10-01 Vertex Pharma Antiproliferation compounds and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
WO2010114179A1 (en) * 2009-04-02 2010-10-07 Mitsubishi Tanabe Pharma Corporation 3-[1,4]oxazepane-4-pyrimidone derivatives
US20110136787A1 (en) * 2009-12-04 2011-06-09 Ryan Craig Schoenfeld Diphenyl azepane, diazepane and oxazepane derivatives and uses thereof

Also Published As

Publication number Publication date
KR102813581B1 (ko) 2025-05-29
US12195453B2 (en) 2025-01-14
IL301501B2 (en) 2024-10-01
ES2919572T3 (es) 2022-07-27
AR114496A1 (es) 2020-09-09
AU2019261308A1 (en) 2020-10-22
EP3784666B1 (en) 2022-03-16
HRP20220710T1 (hr) 2022-07-22
PT4043460T (pt) 2024-09-10
EP4043460A1 (en) 2022-08-17
AU2019261308B2 (en) 2022-09-08
SG11202009500QA (en) 2020-11-27
HUE058746T2 (hu) 2022-09-28
PL3784666T3 (pl) 2022-07-18
TW202012400A (zh) 2020-04-01
CY1125433T1 (el) 2025-05-09
CN112236428A (zh) 2021-01-15
FI4043460T3 (fi) 2025-05-09
IL301501B1 (en) 2024-06-01
IL278142B1 (en) 2023-07-01
US20250188070A1 (en) 2025-06-12
CA3098335A1 (en) 2019-10-31
ES2987356T3 (es) 2024-11-14
HUE067936T2 (hu) 2024-11-28
IL278142A (en) 2020-11-30
PT3784666T (pt) 2022-06-06
SMT202200308T1 (it) 2022-09-14
JP2023101824A (ja) 2023-07-21
BR112020020940A2 (pt) 2021-03-02
SI3784666T1 (sl) 2022-07-29
DK3784666T3 (da) 2022-06-20
MX2020011089A (es) 2020-11-06
ZA202006071B (en) 2024-01-31
WO2019209759A1 (en) 2019-10-31
IL301501A (en) 2023-05-01
LT3784666T (lt) 2022-06-10
EP3784666A1 (en) 2021-03-03
EP4043460B1 (en) 2024-06-05
US20230150993A1 (en) 2023-05-18
KR20210005151A (ko) 2021-01-13
US10815225B2 (en) 2020-10-27
PL4043460T3 (pl) 2024-10-28
US20190322658A1 (en) 2019-10-24
JP7304892B2 (ja) 2023-07-07
DK4043460T3 (da) 2024-08-26
IL278142B2 (en) 2023-11-01
JP2021522242A (ja) 2021-08-30
RS63281B1 (sr) 2022-06-30
HRP20241163T1 (hr) 2024-11-22
CN112236428B (zh) 2025-04-01
US11440907B1 (en) 2022-09-13

Similar Documents

Publication Publication Date Title
US11780837B2 (en) CXCR4 inhibitors and uses thereof
US20210363139A1 (en) Cxcr4 inhibitors and uses thereof
JP7304892B2 (ja) 抗増殖性化合物およびその使用
EP3846793B1 (en) Eif4e inhibitors and uses thereof
TW202423917A (zh) Cdk2抑制劑及其用途
RU2811969C2 (ru) Антипролиферативные соединения и их применения
HK40078355B (en) Antiproliferation compounds and uses thereof
HK40078355A (en) Antiproliferation compounds and uses thereof
HK40047065B (en) Antiproliferation compounds and uses thereof
HK40047065A (en) Antiproliferation compounds and uses thereof
WO2024264070A2 (en) Akt inhibitors